Glenn Dubin - Jan 3, 2023 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Director
Signature
/s/ Jolie M. Siegel, Attorney-in-Fact
Stock symbol
CCCC
Transactions as of
Jan 3, 2023
Transactions value $
$11,006
Form type
4
Date filed
1/4/2023, 03:16 PM
Previous filing
Oct 4, 2022
Next filing
Apr 4, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCCC Common Stock Award $11K +1.73K +49.15% $6.38 5.24K Jan 3, 2023 Direct F1, F2
holding CCCC Common Stock 771K Jan 3, 2023 By DF Investment Partners LLC F3
holding CCCC Common Stock 20K Jan 3, 2023 By G&E Dubin Family Foundation F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.
F2 The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 3, 2023.
F3 Shares held directly by DF Investment Partners LLC ("DFIP"). The Reporting Person serves as managing member of DFIP and may be deemed to exercise voting and investment power over the shares held by DFIP. The Reporting Person disclaims beneficial ownership of the shares held by DFIP except to the extent of his pecuniary interest therein.
F4 Shares held directly by G&E Dubin Family Foundation. The Reporting Person may be deemed to exercise voting and investment power over the shares held by G&E Dubin Family Foundation and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.